VuCOMP Gets FDA Approval for Mammo CAD System
Computer-aided detection system developer VuCOMP Inc. has received FDA premarket approval for its film mammography CAD software.
Computer-aided detection system developer VuCOMP Inc. has received FDA premarket approval for its film mammography CAD software. This is the first new mammography CAD system approved by the FDA since 2007, the company said.
M-Vu is indicated for use in screening mammography to identify areas consistent with breast cancer for radiologist review after completing an initial read, according to the company.
In a reader study at the University of North Carolina at Chapel Hill, physicians using the M-Vu CAD system were more effective at reading mammograms and demonstrated a significant increase in the ability to discriminate between cancer and noncancer, according to VuCOMP.
The company will be providing a digital version of the system in the “near future,” VuCOMP president and CEO Jeff Wehnes said in a statement.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
